Collecting Tumor Cells

Test examining 22 genes

Who can it help?

Patients with common solid tumours – this includes lung, breast and colorectal cancers, as well as melanoma.

What does it do?

Analyses 22 genes within a tumour to suggest which NICE approved treatments may be right for your patient – and also gives additional information that may be useful in identifying potential off-label treatments and/or clinical trials.

Why should I choose it?

It can be much more cost effective – and quicker – than carrying out multiple single gene tests consecutively.

Which genes are covered?

AKT1, ALK, BRAF, CTNNB1, DDR2, EGFR, ERBB2, ERBB4, FBXW7, FGFR1, FGFR2, FGFR3, KRAS, MAP2K1, MET, NOTCH1, NRAS, PIK3CA, PTEN, SMAD4, STK11, TP53
DNA Strand

Test examining 50 genes

Who can it help?

Patients with common solid tumours – this includes lung, breast and colorectal cancers, as well as melanoma and others.

What does it do?

Analyses 50 genes within a tumour to suggest which NICE approved treatments may be right for your patient – and also gives extended additional information that may be useful in identifying potential off-label treatments and/or clinical trials.

Why should I choose it?

As well as being cost effective and quick, this examines more genes than our core test – giving more information and potentially more options for patients.

Which genes are covered?

ABL1, AKT1, ALK, APC, ATM, BRAF, CDH1, CDKN2A, CSF1R, CTNNB1, EGFR, ERBB2, ERBB4, EZH3, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1, IDH2, JAK2, JAK3, KDR, KIT, KRAS, MET, MLH1, MPL, NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4, SMARCB1, SMO, SRC, STK11, TP53, VHL
Realtime PCR Curves

Plasma based & Rapid-turnaround single gene tests

Who can it help?

Patients with common solid tumours  – this includes lung and colorectal cancers as well as melanoma.

 What does it do?

Examines a single gene at a limited number of sites that have been strongly associated with response or resistance to a specific type of approved therapy in certain cancer types. Occasionally, such tests may also be performed to help refine a diagnosis of give prognostic information

Why should I choose it?

As long as the sample is suitable, results will be delivered within a maximum of 2 working days. So it’s useful when time is critical – when circumstances mean you can’t wait for a comprehensive test.

Which genes are covered?

BRAF: Common variants at codon 600

EGFR: Common variants at codons 719, 768, 790, 858, 861 & Common exon 19 deletions/exon 20 insertions

(Can be performed on fixed tissue and circulating tumour DNA isolated from plasma)

KRAS: Common variants at codons 12, 13, 59, 61, 117, 146

NRAS: Common variants at codons 12, 13, 59, 61, 117

Full details on our panels, including downloadable lists of all the variants evaluated, can be found on our NGS Assay Details page.

Also in development:

1) Our combined hotspot/gene fusion test

While our current tests look for relativley small-scale genetic variations of interest (hotspots), we’re all set to launch a new test that also looks for larger scale genetic alterations known as gene fusions. This will be extremely useful for clinicians as, in addition to opening up a whole new range of clinical trial options, it will mean that many routine cases will not need separate tests performing at different laboratories using different technologies. Overall, this should be more time and cost effective, it will also help us to conserve limited biopsy material and allow better integration / interpretation of the data collectively within a single report.

This assay is currently available in a Research Use Only (RUO) context, and must NOT be used instead of clinically validated test to determine routine standard of care options.

More details on the panel contents can be found on our NGS Assay Details page.

2) MSI & MLH-1 promoter methylation status testing.

Coming online late 2017/early 2018, these tests are being launched in line with the updated NICE guidelines relating to Lynch Syndrome pre-screening.

B- and T-cell clonality

We also offer tests to allow the assessment of B- and T-cell clonal expansion in suspected lymphoproliferative diseases. Download a referral form here.